Evidence that clozapine directly interacts on the GABAB receptor

NeuroReport

Volumn 22, Issue 13, 2011, Pages 637-641

  Wu, Ying ^a,b   Blichowski, Monica ^a,d   Daskalakis, Zafiris J ^a,d   Wu, Zhouyou ^a,d   Liu, Chun C ^a   Cortez, Miguel A ^a,b   Snead III, Orlando Carter ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

3H CGP54626A; clozapine; GABA Breceptor N desmethylclozapine; schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; CLOZAPINE; NORCLOZAPINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ANTAGONISM; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CLOZAPINE; GABA ANTAGONISTS; HEK293 CELLS; HUMANS; MICE; RECEPTORS, GABA-B;

EID: 80052023560     PISSN: 09594965     EISSN: 1473558X     Source Type: Journal    
DOI: 10.1097/WNR.0b013e328349739b     Document Type: Article

References (23)

1. Essali A, Al-Haj Haasan N, Li C, Rathbone J. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2009; 1:CD000059.
2. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001; 52: 503-517. (Pubitemid 32195338)
3. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatr 2006; 163: 600-610. (Pubitemid 44464569)
4. Daskalakis ZJ, George TP. Clozapine GABA(B), and the treatment of resistant schizophrenia. Clin Pharmacol Ther 2009; 86:442-446.
5. Goei VL, Choi J, Ahn J, Bowlus CL, Raha CR, Gruen JR. Human gammaaminobutyric acid B receptor gene: complementary DNA cloning, expression, chromosomal location, and genomic organization. Biol Psychiatr 1998; 44:659-666. (Pubitemid 28496780)
6. Mizukami K, Ishikawa M, Hidaka S, Iwakiri M, Sasaki M, Iritani S. Immunohistochemical localization of GABAB receptor in the entorhinal cortex and inferior temporal cortex of schizophrenic brain. Prog Neuropsychopharmacol Biol Psychiatr 2002; 26:393-396. (Pubitemid 34038071)
7. Arai S, Takuma K, Mizoguchi H, Ibi D, Nagai T, Kamei H, et al. GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice. Eur J Pharmacol 2009; 602:101-104.
8. Bortolato M, Frau R, Orrù M, Piras AP, Fà M, Tuveri A, et al. Activation of GABAB receptors reverses spontaneous gating deficits in juvenile DBA/2J mice. Psychopharmacology 2007; 194:361-369. (Pubitemid 47389346)
9. Blein S, Hawrot E, Barlow P. The metabotropic GABA receptor: molecular insights and their functional consequences. Cell Mol Life Sci 2000; 57:635-650. (Pubitemid 30311434)
10. Freedman R, Adler LE, Waldo MC, Patchman E, Franks RD. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol Psychiatr 1983; 18:537-551. (Pubitemid 13135325)
11. Adler LE, Olincy A, Cawthra EM, McRae KA, Harris JG, Nagamoto HT, et al. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatr 2004; 161:1822-1828. (Pubitemid 39314676)
12. Daskalakis ZJ, Christensen BK, Fitzgerald PB, Moller B, Fountain SI, Chen R. Increased cortical inhibition in persons with schizophrenia treated with clozapine. J Psychopharmacol 2008; 22:203-209. (Pubitemid 351322858)
13. Siebner HR, Dressnandt J, Auer C, Conrad B. Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia. Muscle Nerve 1998; 21:1209-1212. (Pubitemid 28355572)
14. Liu SK, Fitzgerald PB, Daigle M, Chen R, Daskalakis ZJ. The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia. Biol Psychiatr 2009; 65:503-509.
15. Kantrowitz J, Citrome L, Javitt D. Receptors, schizophrenia and sleep dysfunction: a review of the relationship and its potential clinical and therapeutic implications. CNS Drugs 2009; 23:681-691.
16. Kuoppamaki M, Syvalahti E, Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT1C receptor antagonists. Eur J Pharmacol 1993; 245:179-182. (Pubitemid 23115053)
17. Franklin KBJ, Paxinos G.The Mouse Brain in Stereotaxic Coordinates. San Diego: Academic Press; 1997.
18. Wu Y, Ali S, Ahmadian G, Liu CC, Wang YT, Gibson KM, et al. Chydroxybutyric acid (GHB) and c-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence. Neuropharmacology 2004; 47:1146-1156. (Pubitemid 39572706)
19. Bettler B, Tiao JY. Molecular diversity, trafficking and subcellular localization of GABAB receptors. Pharmacol Ther 2006; 110:533-543.
20. Sarker S, Weissensteiner R, Steiner I, Sitte HH, Ecker GF, Freissmuth M, et al. The high-affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter. Mol Pharmacol 2010; 78:1026-1035.
21. Thuault SJ, Brown JT, Sheardown SA, Jourdain S, Fairfax B Spencer JP, et al. The GABA(B2) subunit is critical for the trafficking and function of native GABAB receptors. Biochem Pharmacol 2004; 68:1655-1666. (Pubitemid 39286470)
22. Bun H, Disdier B, Aubert C, Catalin J. Interspecies variability and drug interactions of clozapine metabolism by microsomes. Fundam Clin Pharmacol 1999; 13:577-581.
23. Kuner R, Köhr G, Grünewald S, Eisenhardt G, Bach A, Kornau HC. Role of heteromer formation in GABAB receptor function. Science 1999; 283:74-77. (Pubitemid 29044849)